Pancreatic Diseases – Pipeline Review, H2 2012

Pancreatic Diseases – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Pancreatic Diseases - Pipeline Review, H2 2012', provides an overview of the Pancreatic Diseases therapeutic pipeline. This report provides information on the therapeutic development for Pancreatic Diseases, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pancreatic Diseases. 'Pancreatic Diseases - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Pancreatic Diseases.
- A review of the Pancreatic Diseases products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Pancreatic Diseases pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Pancreatic Diseases.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Pancreatic Diseases pipeline depth and focus of Pancreatic Diseases therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Pancreatic Diseases Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Pancreatic Diseases 7
Pancreatic Diseases Therapeutics under Development by Companies 9
Pancreatic Diseases Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Discovery and Pre-Clinical Stage Products 14
Comparative Analysis 14
Pancreatic Diseases Therapeutics – Products under Development by Companies 15
Pancreatic Diseases Therapeutics – Products under Investigation by Universities/Institutes 16
Companies Involved in Pancreatic Diseases Therapeutics Development 17
Eli Lilly and Company 17
Axcan Pharma Inc. 18
Angion Biomedica Corp. 19
Xenome Ltd. 20
Stelic Institute & Co. 21
Pancreatic Diseases – Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
Liprotamase - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Zenpep - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
G Family Inhibitor For Type 2 Diabetes And Chronic Pancreatitis - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Aprotinin - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Dexamethasone - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
ND-07 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
GALA - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
ANG-3186 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Pancreatic Diseases Therapeutics – Drug Profile Updates 36
Pancreatic Diseases Therapeutics – Discontinued Products 38
Pancreatic Diseases Therapeutics - Dormant Products 39
Pancreatic Diseases – Product Development Milestones 40
Featured News & Press Releases 40
Jul 14, 2011: Aptalis Pharma Receives FDA Approval Of 25,000 Lipase-Unit Strength Of ZENPEP 40
Jun 29, 2011: Amsterdam Molecular Therapeutics's Glybera Significantly Reduces Risk Of Pancreatitis In LPLD Patients 40
Jun 17, 2011: Aptalis Pharma Receives FDA Approval For New Low Strength Of ZENPEP 41
Apr 15, 2011: Lilly Receives Complete Response Letter From FDA For Liprotamase For Treatment Of Exocrine Pancreatic Insufficiency 41
Feb 11, 2011: Axcan Completes Acquisition of Eurand and Commences Subsequent Offering Period 42
Jan 12, 2011: Lilly Announces FDA Panel Recommendation For Liprotamase 42
Jan 12, 2011: Eurand Announces Agreement With Nycomed for ZENPEP in Russia-CIS 42
Oct 21, 2010: Eurand Presents Data On ZENPEP Without Proton Pump Inhibitors Or H2 Receptor Antagonists For Treatment Of Pancreatic Insufficiency 43
Oct 21, 2010: Eurand Presents Data on ZENPEP Without Proton Pump Inhibitors or H2 Receptor Antagonists in Patients With CF and Pancreatic Insufficiency 44
Jun 17, 2010: Eurand Announces Data on Switching Cystic Fibrosis Patients With Exocrine Pancreatic Insufficiency From Unapproved PEPs to FDA-Approved ZENPEP 44
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 47
Disclaimer 47

List of Tables
Number of Products Under Development for Pancreatic Diseases, H2 2012 7
Products under Development for Pancreatic Diseases – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Early Clinical Stage Development, H2 2012 13
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 16
Eli Lilly and Company, H2 2012 17
Axcan Pharma Inc., H2 2012 18
Angion Biomedica Corp., H2 2012 19
Xenome Ltd., H2 2012 20
Stelic Institute & Co., H2 2012 21
Assessment by Monotherapy Products, H2 2012 22
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Stage and Molecule Type, H2 2012 26
Pancreatic Diseases Therapeutics – Drug Profile Updates 36
Pancreatic Diseases Therapeutics – Discontinued Products 38
Pancreatic Diseases Therapeutics – Dormant Products 39

List of Figures
Number of Products under Development for Pancreatic Diseases, H2 2012 7
Products under Development for Pancreatic Diseases – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Early Clinical Stage Products, H2 2012 13
Discovery and Pre-Clinical Stage Products, H2 2012 14
Assessment by Monotherapy Products, H2 2012 22
Assessment by Route of Administration, H2 2012 23
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Molecule Type, H2 2012 25
Assessment by Stage and Molecule Type, H2 2012 26